# Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis

> **NCT01687179** · PHASE1 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 14 (actual)

## Conditions studied

- Lymphangioleiomyomatosis

## Interventions

- **DRUG:** "Sirolimus" and "Hydroxychloroquine" 200 mg
- **DRUG:** "Sirolimus" and "Hydroxychloroquine" 400 mg

## Key facts

- **NCT ID:** NCT01687179
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2018-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01687179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01687179, "Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01687179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*